Gemcitabine Hydrochloride Basic information
|
Product Name: |
Gemcitabine Hydrochloride |
|
Synonyms: |
2',2'-difluorodeoxycytidinemonohydrochloride;2'-deoxy-2',2'-difluorocytidinemonohydrochloride;2'-deoxy-2',2'-difluoro-cytidinmonohydrochloride;gemzar;ly188011;ly188011hydrochloride;2',2'-DIFLUORO-2'-DEOXYCYTIDINE;2'-DEOXY-2',2'-DIFLUOROCYTIDINE |
|
CAS: |
122111-03-9 |
|
MF: |
C9H12ClF2N3O4 |
|
MW: |
299.66 |
|
EINECS: |
601-823-3 |
Gemcitabine Hydrochloride Chemical Properties
| Melting point | >250°C dec. |
| alpha | D +48°; 365 +257.9° (c = 1.0 in deuterated water) |
| storage temp. | 2-8°C |
| solubility | H2O: ≥10mg/mL |
| form | White powder |
| color | White |
| λmax | 268nm(H2O)(lit.) |
| Merck | 14,4386 |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. |
Gemcitabine Hydrochloride Usage And Synthesis
| Description | Gemcitabine is a novel nucleoside analog that was launched in 1995 in the Netherlands for the treatment of non-small cell lung cancer (nsclc) and in Sweden for pancreatic cancer. Gemcitabine is a prodrug which is phosphorylated intracellularly by deoxycytadine kinase to its active forms, the di- and triphosphates which bind to DNA competitively. This insertion inhibits processes required for DNA synthesis and metabolism, the essential function for both cell replication and repair. Furthermore, gemcitabine displays an extraordinary array of self-potentiating mechanisms that increase the concentration and prolong the retention of its active nucleotides in tumor cells. The title compound has shown activity against a wide spectrum of human solid tumors including colon, mammary, breast, bladder cancers. Synergistic activity of gemcitabine with other anticancer agents such as cisplatin has been reported. |
| Chemical Properties | White crystalline granular, odorless |
| Uses | An antineoplastic |
Gemcitabine Hydrochloride CAS NO.122111-03-9 is a new generation of antimetabolites, which is a cell cycle specific drug, which mainly acts on the DNA synthesis phase, that is, S phase cells. Under certain conditions, the progression from G1 phase to S phase can also be prevented, and it has strong anti-cancer activity against non-small cell lung cancer (NSCLC). Foreign studies have shown that gemcitabine hydrochloride alone has an effective rate of 18% to 35% in the treatment of NSCLC. The effective rate of combined cisplatin in the treatment of non-small cell lung cancer (NSCLC) was 41.7%. The effective rate of carboplatin for advanced NSCLC is 16%, which is similar to cisplatin, but has low toxicity, especially gastrointestinal reactions, bone marrow suppression, kidney and peripheral nerves. Combined with carboplatin, it has mutual coordination and additive effects, and can produce higher efficacy.
Hot Tags: gemcitabine hydrochloride cas no.122111-03-9, China, manufacturers, suppliers, factory, custom, wholesale
